How has the antisense & rnai therapeutics market evolved, and where is it heading next? The antisense & RNAi therapeutics market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to a rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in the elderly population, and economic growth in emerging markets. The antisense & RNAi therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to an increase in healthcare access, rising prevalence of cancer, and increasing demand for antisense and RNAi therapeutics due to COVID-19. Major trends in the forecast period include focus efforts towards the research and development of RNA therapeutics for orphan diseases, use of nanoparticles, development of new and improved antisense and RNAi therapeutics, and collaboration with other companies for product innovation and to drive revenues. Get Your Free Sample of The Global Antisense & RNAi Therapeutics Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp What are the key drivers behind the rapid expansion of the antisense & rnai therapeutics market? The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. For instance, in January 2024, according to the report published by the American Heart Association, a US-based organization, the age-adjusted death rate from cardiovascular diseases increased to 233.3 per 100,000, reflecting a 4.0% rise from the previous year. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market. What is the segmentation for the antisense & rnai therapeutics market? The antisense & RNAi therapeutics market covered in this report is segmented – 1) By Technology: RNA Interference, Antisense RNA 2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods 3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications Subsegments: 1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics 2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides Order your report now for swift delivery https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report Who are the most influential companies in the antisense & rnai therapeutics market? Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical What are the most influential trends expected to drive the antisense & rnai therapeutics market forward? Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives, such as collaborations and partnerships to sustain in the increasingly competitive market. Strategic collaboration is a business strategy that involves two or more companies working together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company offering services for the discovery of peptides, partnered with SanegeneBio Inc., a UK-based company involved in the developing novel RNAi-based medicines for the identification of tissue-specific delivery of RNA therapeutics for efficient gene knockdown, aiming to develop a portfolio of advanced RNAi therapeutics. The collaboration encompasses hit identification and cell-based internalization studies, with Sanegene having the option to further develop the hits derived from the screening activities, leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine enables the screening of large peptide libraries, offering faster discovery times for relevant peptide leads based on affinity and functional screens. What are the major regional insights for the antisense & rnai therapeutics market, and which region holds the top position? The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain What Does The Antisense & RNAi Therapeutics Market Report 2025 Offer? The antisense & rnai therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities. Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs. Purchase the exclusive report now to unlock valuable market insights: https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389 About The Business Research Company With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making. Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The new report by Expert Market Research titled, ‘Global Antisense and RNAi Therapeutics Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global antisense and RNAi therapeutics market, assessing the market based on its segments like end-product forms, equipment types, and applications.
The sample report shall be delivered to you within 24 hours.Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/antisense-and-rnai-therapeutics-market/requestsampleThe key highlights of the report include:Market Overview (2016-2026)Forecast CAGR (2021-2026): 8.5%Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/antisense-and-rnai-therapeutics-marketIndustry Definition and Major SegmentsSpecific and highly effective gene silencing is possible due to antisense and RNAi therapeutics.
Oncology, cardiovascular disease, respiratory disorders, renal disease, neurodegenerative disorders, genetic disorders, infectious diseases, and other conditions are all treated with it.The Antisense and RNAi therapeutics industry can be divided based on:TechnologyRNA InterferenceSiRNAMiRNAAntisense RNARoute of AdministrationPulmonary DeliveryIntravenous InjectionsIntra-dermal InjectionsIntraperitoneal InjectionsTopical DeliveryMarket TrendThe global antisense and RNAi therapeutics industry is propelled by a deep understanding of gene function for disease management via the use of malfunctioning genes and the control of their gene expression.
Various collaborations between pharmaceutical companies and contract research organisations working to improve drug delivery are also driving the market.The global antisense and RNAi therapeutics market is being driven by the rising prevalence of infectious diseases and neurodegenerative disorders.
Nanocarriers have been shown to improve bioavailability, transporting limits of siRNA payload, and providing high cooperation with target cells.However, stringent regulations, a lengthy product approval process, high development costs, and a relatively small number of patients are just a few of the factors that contribute to the high cost of RNA interference drugs, which is expected to slow the market growth of antisense and RNAi therapeutics in the coming years.Key Market PlayersThe major players within the market are OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceuticals, Benitec Biopharma Ltd, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Antisense Therapeutics Ltd. and others.
The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of those market players.Read More Reports:-Global Sodium Monochloro Acetate Market: https://www.expertmarketresearch.com/reports/sodium-monochloro-acetate-marketGlobal Epigenetics Market: https://www.expertmarketresearch.com/reports/epigenetics-marketGlobal Digital Therapeutics Market: https://www.expertmarketresearch.com/reports/digital-therapeutics-marketGlobal Coco Coir Market: https://www.expertmarketresearch.com/reports/coco-coir-marketGlobal Metal Finishing Market: https://www.expertmarketresearch.com/reports/metal-finishing-marketGlobal Probiotic Supplements Market: https://www.expertmarketresearch.com/reports/probiotic-supplements-marketGlobal Styrene Market: https://www.expertmarketresearch.com/reports/styrene-marketGlobal Brain Computer Interface Market: https://www.expertmarketresearch.com/reports/brain-computer-interface-marketGlobal Wireless Microphone Market: https://www.expertmarketresearch.com/reports/wireless-microphone-marketGlobal Sodium Chlorite Market: https://www.expertmarketresearch.com/reports/sodium-chlorite-marketNote 2: As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours.
Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025.
RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts.
The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample Market Synopsis of Antisense & RNAi Therapeutics Market: Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come.
However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years.
Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period.
